DiscoverMenopauseWize: Navigating Through Menopause with Knowledge and WisdomChange in the FDA Black Box Warning: What Does it Mean for Women and Their Providers
Change in the FDA Black Box Warning: What Does it Mean for Women and Their Providers

Change in the FDA Black Box Warning: What Does it Mean for Women and Their Providers

Update: 2025-11-22
Share

Description

Have something to share? Send us a text!

In this episode of the MenopauseWize Podcast, Dr. Sukhpreet Patel sits down with Dr. Shafeena Premji, a nationally recognized menopause expert and founder of multiple women-centered clinics in Calgary, including the upcoming Milestone Menopause Centre of Southern Alberta. Known for her ability to translate evidence into compassionate, accessible care, Dr. Premji helps us unpack one of the biggest regulatory shifts in women’s health in years: the FDA’s removal of the Black Box Warning from estrogen products.

For decades, the Black Box Warning shaped public perception, prescribing patterns, and women’s fear of hormone therapy. But what exactly was this warning? Why was it applied broadly to all estrogen formulations, from low-dose vaginal estrogen to systemic hormone therapy? And now that the warning is being removed from all estrogen products, what does this change actually mean for women, for clinicians, and for safer, evidence-based menopause care?

Dr. Premji brings clarity to the science, explains the differences between systemic and vaginal estrogen, discusses age and timing of initiation, and offers practical guidance for women who are wondering how to interpret this shift.

Whether you're a clinician navigating counselling conversations or a woman seeking accurate information amidst the noise, this episode will equip you with the facts, the nuance, and the confidence to make informed decisions about hormone therapy in midlife and beyond.

Key Topics Covered:
• What the original Black Box Warning said and why it was created
• The impact of the warning on women’s health, care access, and stigma
• Why the FDA removed the warning and what this reflects about updated evidence
• Differences between systemic and low-dose vaginal estrogen
• How dose, route, and timing influence safety
• What this regulatory shift means for women
• Practical considerations for clinicians and patients
• How to balance evidence, nuance, and individualized care

Tune in for a clear, evidence-based conversation that cuts through fear and confusion.

VaginaWize: The Ultimate Women's Guide to Intimate Health at Midlife and Beyond.

Learn what nobody ever taught you about your intimate health!

GSM-Wize: The Ultimate Provider's Guide to the Genitourinary Syndrome of Menopause

Support the show

The information provided in all episodes of the MenopauseWize podcast, including content shared by Sukhpreet Patel or any guest or representative, is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare consultation, diagnosis, or treatment. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions.

SheRise Healthcare Pvt. Ltd., MenopauseWize, Sukhpreet Patel, or any representative will not be held responsible or liable for any direct, indirect, incidental, or consequential damages arising from the use or reliance on the information provided in this podcast. Listeners are encouraged to use the information at their own discretion and always seek advice from a licensed medical professional before making any healthcare decisions.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Change in the FDA Black Box Warning: What Does it Mean for Women and Their Providers

Change in the FDA Black Box Warning: What Does it Mean for Women and Their Providers

Sukhpreet Patel, MD(ObGyn, India), MPH, HCA-RHC™ HCA-RHNC™ (Canada)